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Summary. Background &Objective: The factor VIII (FVIII) B
domain shares very little amino acid homology with other
known proteins and is not directly necessary for procoagulant
activity. Despite this, missense mutations within the B domain
have been reported in patients with hemophilia A. Given that
theBdomain is dispensable for secretion and function ofFVIII,
we hypothesized that thesemutations should not be causative of
hemophilia A in these patients. Methods: Plasmid vectors
containing B domain missense mutations that were reported to
be associated with moderate/severe hemophilia A (T751S,
D826E, V993L,H1047Y, T1353A,N1441K, L1462P, E1579D,
A1591S, P1641L and S1669L) were analyzed for their effect on
synthesis and secretion compared with FVIII wild-type (WT)
following transient transfection into COS-1 and CHO cells in
vitro. Further, H1047Y, N1441K and E1579D mutants were
expressed in vivo in a hemophilia A mouse model by
hydrodynamic tail-vein injection. Results: FVIII activity and
antigen levels for all mutants expressed into the conditioned
mediaofCOS-1andCHOcellswere similar toFVIIIWT.Also,
plasma expression of thesemutants was similar to FVIIIWT in
hemophilia A mice. An in vivo tail clip bleeding assay also
demonstrated that blood loss from hemophilia A mice
expressing FVIII WT, H1047Y, N1441K and E1579D was
similar. Conclusions: We conclude that most missense
mutations within the FVIII B domain would be unlikely to
lead to severe hemophilia A and that the majority of
such missense mutations represent polymorphisms or non-
pathologic mutations.
Keywords: B domain, factor VIII, genotyping, hemophilia A,
mutations.
Introduction
Factor (F) VIII is a large plasma glycoprotein that functions as
an essential cofactor for the proteolytic activation of FX by
activated FIX within the intrinsic pathway of blood coagula-
tion [1]. Deficiency or dysfunction of FVIII results in hemo-
philia A, which is phenotypically stratified asmild, moderate or
severe disease based on residual plasma FVIII activity of
> 5%, 1%–5%or< 1%, respectively. FVIII is synthesized as
a single-chain polypeptide of approximately 280 kDa with the
domain structure A1-a1-A2-a2-B-ap-A3-C1-C2, with italics
denoting heavy chain acidic regions and a light chain activation
peptide [2,3]. This domain structure is also shared by the
homologous coagulation cofactor, FV. Following synthesis,
cleavage within the B domain results in a variably sized heavy
chain (A1-a1-A2-a2-B, 90–200 kDa) and a light chain (ap-A3-
C1-C2, 80 kDa) that are associated as a heterodimer through a
divalent metal ion linkage between the A1 and A3 domains [4].
The A domains share 35–40% amino acid identity and are
homologous to theA domains of ceruloplasmin andFV. TheC
domains also display 35–40%amino acid identity to each other
and to FV and are homologous to proteins that are capable of
binding negatively charged phospholipids, suggesting a role in
phospholipid interactions [2,3,5].
A database of mutations described as causing hemophilia A
is available on the Internet at The Haemophilia A Mutation,
Structure, Test and Resource Site (HAMSTeRS: http://
hadb.org.uk/; Accessed 12 October 2010). Common gene
derangements include gene inversions, insertions and large and
small gene deletions, typically associated with a severe pheno-
type. However, point mutations (missense, nonsense and
messenger RNA splice-site mutations) represent approximately
70% of the described molecular defects in hemophilia A. The
study of FVIII missense mutations, in particular, has provided
insights on: structure and function of FVIII, mechanisms of
hemophilia A, and risk of inhibitors developing to FVIII
replacement therapy. Over 900 such missense mutations have
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now been described and occur throughout the entire coding
region for FVIII. Although missense mutations have been
shown to interfere with FVIII biosynthesis and secretion, there
are a number of hemophilia A missense mutations that affect
the functional properties of FVIII. These are clustered in
regions known to interact with FIXa, FX, von Willebrand
factor (VWF) and the phospholipid surface or affect the
stability of FVIII after activation by thrombin [6]. However,
those missense mutations characterized to date have all been
located within the A and C domains of FVIII.
The large FVIII B domain is encoded by a single large exon
(exon 14) and roughly spans from amino acids 741 to 1648.
Unlike the other functional domains of the FVIII molecule, the
B domain shares very little amino acid homology with the B
domain of FV. FVIII does share with FV the distinctive
property of having extensive asparagine (N)-linked glycosyla-
tion in its B domain. The B domain alone accounts for 19 of the
25 potential asparagine (N)-linked glycosylation attachment
sites found on the FVIII molecule. While the B domain is not
directly necessary for the central procoagulant activity of
FVIII, more recently it has been shown to play a major role in
the intracellular processing and trafficking of FVIII. In
addition, there is emerging evidence that portions of the B
domain may have functional influences throughout the life
cycle of FVIII [7]. However, nomolecular mechanisms for how
missense mutations within the B domain cause hemophilia A
have been described.
Figure 1 depicts the reported missense mutations within the
FVIII B-domain that have been associated with moderate/
severe hemophilia A. None of these reported mutations
occurred at sites known to be involved in post-translational
modifications within the B domain. In this report we have
characterized these FVIII B domain missense mutations,
including in vitro and in vivo expression and functional analysis,
to elucidate any plausible mechanism for causation of hemo-
philia A. The list of B domain missense mutations analyzed in




FVIII-deficient and normal pooled human plasma were
obtained from George King Biomedical (Overland Park, KS,
USA). Activated partial thromboplastin (automated aPTT
reagent) and CaCl2 were purchased from bioMériux (Durham,
NC,USA).DulbeccomodifiedEaglemedium(DMEM),alpha-
modified essential medium (alpha-MEM) and fetal bovine
serum were purchased from Gibco BRL (Gaithersburg, MD,
USA). COAMATIC was purchased from DiaPharma (West
Chester, OH, USA).Matched-Pair Antibody Set for ELISA of
human Factor VIII antigen was purchased from Affinity
Biologicals (Ancaster, ON, USA). FuGENE-6 transfection
Fig. 1. Missense mutations and sites of key post-translational modifications within the factor (F) VIII B domain. Sites of reported missense mutations
within the FVIII B domain and their reported clinical phenotypes are indicated in the upper portion of the figure. Residues that predict sites of
asparagine(N)-linked glycosylation, tyrosine(Y)-sulfation and proteolytic modification are indicated in the lower portion of the figure.
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reagent was purchased from Roche Applied Science (India-
napolis, IN, USA). QuikChange XL Site-Directed Mutagen-
esis kit was purchased from Stratagene (La Jolla, CA, USA).
Male C57BL/6mice were purchased from JacksonLaboratory.
F8)/) (exon 16 knock-out) hemophilia Amice [16] were housed
under pathogen-free conditions at the University of Michigan
Laboratory AnimalMedicine (ULAM) facility. TheUniversity
Committee on the Use and Care of Animals (UCUCA)
approved the animal protocols.
Plasmid mutagenesis
Mutagenesis was performed within the mammalian expression
vector pMT2 [17] containing the full-length human FVIII
cDNA (NM_000132). Mutant plasmids were generated
through site-directed mutagenesis using the QuikChange XL
protocol as described previously [18,19]. The plasmid contain-
ing the full-length wild-type human FVIII cDNA sequence was
designated FVIII WT. The mutations were confirmed by
restriction enzyme digestion and DNA sequencing.
Plasmid transfection and analysis of in vitro expression
Plasmid DNA of FVIII WT, B domain mutants and control
mutants were transfected into COS-1 monkey kidney cells by
the diethylamino ethanol (DEAE)-dextran method as previ-
ously described [20] and into Chinese hamster ovary (CHO)
cells using FuGENE-6 transfection reagent according to the
manufacturers recommendations. Conditioned medium was
harvested at 60–70 h post-transfection.
Factor VIII activity and antigen analysis
FVIII activity was measured by a: (i) one-stage aPTT clotting
assay on an MLA Electra 750 fibrinometer (Medical Labora-
tory Automation, Pleasantville, NY,USA) by reconstitution of
human FVIII-deficient plasma or (ii) two-stage assay using the
COAMATIC chromogenic assay according to the manufac-
turers instructions. The FVIII plasma standard was FACT
plasma (normal pooled plasma) fromGeorge King Biomedical
for the one-stage aPTT clotting assay. The calibration standard
included with the COAMATIC chromogenic assay is assayed
according to the Fourth International WHO standard. FVIII
antigen was quantified by an anti-FVIII light chain sandwich
ELISA according to the manufacturers instructions.
Plasmid expression in vivo by hydrodynamic tail-vein
injection into the hemophilia A (exon 16)/)) mouse model
A F8 exon 16 knock-out mouse model of hemophilia A was
used to analyze the in vivo expression of the FVIII B domain
mutants. Plasmid DNA (100 ug) was diluted in 2.0 mL
Lactated Ringers and infused over 10 s into the tail vein
[21,22]. Peripheral blood was collected from the retro-orbital
venous plexus at 24 h and mixed in 10% volume of 3.8%
sodium citrate. Plasma was prepared by centrifugation of the
blood at 2000 g for 15 min. FVIII activity and antigen levels
were analyzed byCOAMATIC chromogenic assay and human
FVIII-specific ELISA.
Murine tail clip bleeding assay
A quantitative in vivo hemostasis assay was performed at
between 24 and 48 h after hydrodynamic tail vein injection.
Mice were anesthetized (ketamine 80 mg kg)1; xylazine
5 mg kg)1 IP) and the tail was placed on a heat pad at 37 C
for 5 min. Next, the tail was transected with a sterile razor
blade over a lateral tail vein at a position where the diameter of
the tail was approximately 1.5 mm. After transection, the tail
was immediately placed in a 15-mL falcon tube filled with 0.9%
NaCl warmed to 37 C. Theweight of lost bloodwasmeasured
by a micro balance within a 10-min window. Immediately after
the conclusion of the bleeding assay, peripheral blood was
collected from the mouse retro-orbital venous plexus and
Table 1 Factor VIII B domain missense mutations analyzed in the present study
Nucleotide change* Amino acid change Reported clinical phenotype HAMSTeRS References
c.2309 C > G T751S (T770S) Mild No [8]
c.2535 C > A D826E (D845E) Severe No [9]
c.3034 G > C V993L (V1012L) Severe Yes [10]
c.3196C > T H1047Y (H1066Y) Severe Yes [11]
c.4114 A > G T1353A (T1372A) Severe No [12]
c.4380T > A N1441K (N1460K) Cross-reacting material-reduced;
Mild/moderate
Yes [13]
c.4442T > C L1462P (L1481P) Unknown Yes [13]
c.4794 G > T E1579D (E1598D) Severe Yes Unpublished
c.4828 G > T A1591S (A1610S) Severe Yes [14]
c.4979 C > T P1641L (P1660L) Severe Yes [15]
c.5063 C > T S1669L (S1688L) Moderate No [12]
*DNA mutation numbering is based on cDNA sequence (GENBANK # NM_000132), with nucleotide +1 corresponding to A of the ATG
translation initiation codon. Amino acid numbering is for the mature processed protein, with the first alanine numbered as +1, and is repre-
sentative of the published literature and the factor VIII mutation reference database. The corresponding Human Gene Variation Sequence
(HGVS)–type numbering is shown in parentheses.
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mixed in 10% volume of 3.8% sodium citrate. Plasma was
prepared by centrifugation of the blood at 2000 g for 15 min.
FVIII activity was analyzed by COAMATIC chromogenic
assay.
Statistical analysis
Data are expressed as mean values ± SD. Statistical signifi-
cance was determined by a two-sided Student t-test and
established at P < 0.05.
Results
Analysis of FVIII B domain mutants in silico
To compare amino acid sequence variation between species at
sites of FVIII B domain hemophilia-associated missense
mutations, we utilized the Basic Local Alignment Search Tool
(BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi). Amino acid
alignments were performed by MacVector (Symantec, Cuper-
tino, CA, USA). Although there was relatively high conserva-
tion of the residues between species at the homologous sites for
the B domain missense mutation, especially at position 1047,
the greatest divergence was at amino acid 1241 (Table 2).
Interestingly, some of the reported hemophilia A mutations
appear as a native sequence in other species.
We also investigated whether missense mutations within the
FVIII B domain associatedwith hemophilia Awere reported in
normal population studies by searching the National Center
for Biotechnology Information (NCBI) database of SNPs
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp, Accessed
12 October 2010). Out of 10 SNPs also reported to result in
missense mutations of FVIII, four were found in the B domain
(data not shown).
We utilized three software tools available online, namely,
POLYPHEN (http://genetics.bwh.harvard.edu/pph/), SIFT (http://
sift.jcvi.org/) and ALIGN GVGD (http://agvgd.iarc.fr/) to
predict whether these missense substitutions were likely to be
damaging. Of all the B domain mutations, Polyphen
predicted only H1047Y and N1441K to be possibly dam-
aging, while all the others were considered to be benign.
Similarly, SIFT analysis indicated that only E1038K and
N1441K might affect FVIII function and it is to be noted
here that both of these were low confidence predictions.
Align GVGD analysis suggested that H1047Y, N1441K,
L1462P, A1591S, P1641L and S1669L were most likely to
affect function while the rest were benign. The utility of these
in silico prediction tools was further underscored by the fact
that all three of them predicted the A and C domain
mutations, namely, R593C and R2150C, included as controls
in this study, to be deleterious.
Expression of FVIII B-domain mutants is similar to WT in
COS-1 and CHO cells
FVIII WT and B-domain mutants were compared after
transient DNA transfection into COS-1 monkey kidney cells
in vitro. FVIII activity and antigen levels were measured by a
one-stage clotting assay and FVIII-specific ELISA, respec-
tively, from the conditioned media 60–70 h after transfection.
As controls for our experimental approach, previously well-
characterized FVIII A and C domain mutants, namely,
A284E, R593C and R2150C, were included in our assays. All
B-domain mutants exhibited FVIII activity and antigen








T751S T/T/T/A/T/T/T/S Benign Tolerated Likely
D826E D/D/E/D/E/E/D/H Benign Tolerated Less likely
V993L V/V/V/D/V/V/V/- Benign Tolerated Least likely
E1038K E/E/E/E/-/E/E/E Benign Affects function Likely
H1047Y H/H/H/H/-/H/Y/H Possibly damaging Tolerated Most likely
D1241E D/E/E/Y/G/E/-/E Benign Tolerated Less likely
T1353A T/T/T/K/-/T/T/K Benign Tolerated Likely
N1441K N/N/N/N/N/N/N/D Possibly damaging Affects function Most likely
L1462P L/V/L/P/L/L/L/P Benign Tolerated Most likely
E1579D E/E/E/M/E/E/E/Q Benign Tolerated Less likely
A1591S A/A/A/S/A/A/D/R Benign Tolerated Most likely
P1641L P/P/P/P/P/P/S/L Benign Tolerated Most likely
S1669L S/S/S/T/S/S/S/V Benign Tolerated Most likely
A284E A/A/A/A/A/A/A/A Benign Tolerated Most likely
R593C R/R/R/R/R/R/R/R Probably damaging Affects function Most likely
R2150C R/R/R/R/R/R/R/R Probably damaging Affects function Most likely
H, human; CM, common marmoset; D, dog; M, mouse; P, pig; B, bat; Rb, rabbit; R, rat. Non-conserved amino acids are in bold; divergent amino
acids are italicized; reported mutations appearing as native sequences in other species are underlined. *Factor VIII conservation across species.
Low confidence prediction.
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levels similar to FVIII WT(Fig. 2A). To determine if the
observations were cell-line specific, the same experiments were
repeated in CHO cells and no difference was observed for the
B domain mutants compared with FVIII WT (Fig. 2B). Of the
controls, A284E displayed a mild impairment of FVIII activity
while FVIII antigen levels were similar to those of FVIII WT.
In the case of R593C, a mild to moderate impairment of FVIII
activity and a moderate to severe impairment of antigen levels
were observed. R2150C on the other hand, displayed a mild
phenotype with both FVIII activity and antigen levels.
B domain mutants express efficiently in vivo in the hemophilia
A mouse model
We next compared the in vivo expression for select B domain
mutants with FVIIIWT in the hemophilia Amousemodel.We
chose H1047Y and N1441K because they were considered
possibly damaging by the different prediction tools. In
addition, we also chose the known polymorphism D1241E
and E1579D, which is an unpublished entry in HAMSTeRS
database with a severe phenotype. We also included A284E
and R2150C as control mutants. We induced transient
expression in the liver of hemophilia A mice using a hydro-
dynamic tail vein injection of plasmid DNA. No statistically
significant difference in mean plasma levels was found between
FVIIIWT,H1047Y,D1241E,N1441K and E1579Dmeasured
at 265.1 mU mL)1 (range, 10.8–734.1), 203.7 mU mL)1 (96.1–
368.3), 208.4 mU mL)1 (25.51–608.1), 335.5 mU mL)1 (150–
485) and 212 mU mL)1 (40.5–720), respectively (Fig. 3A). The
mean plasma levels of the controls A284E and R2150C were
12 mU mL)1 (9.4–38.3) and 84.1 mU mL)1 (18.4–143),
respectively, and were significantly lower than FVIII WT
(P < 0.05).
B domain mutants exhibit effective hemostasis in vivo in the
hemophilia A mouse model
To investigate the functional effect of select FVIII B domain
mutants, we utilized an in vivo tail clip bleeding assay in the
hemophilia A mouse model (n ‡ 5). The mean quantitation of
blood loss in untreated HA mice was 633.6 mg (range, 395–
737; n = 5), while in C57BL/6J control mice, it was 115 mg
(82–165). The mean blood loss measured for FVIII WT,
H1047Y, D1241E, N1441K and E1579D was 216.2 mg (26–
453), 260 mg (65–573), 278.14 mg (12–532), 169.4 mg (57–299)
and 134.33 mg (25–488), respectively (Fig. 3B). No statistically
significant difference was observed between FVIII WT and the

































































































































Fig. 2. Expression of factor (F) VIII B domainmissensemutants is similar to wild type (WT) in COS-1 andCHOcells. FVIII activity ( ) and antigen levels
(h) in the conditionedmedia of COS-1 (A) andCHO (B) cells weremeasured byAPTT andELISA, respectively, at 60–70 h following transfectionwith the
indicated FVIII constructs. Data are reported as percentages of FVIII WT expression. Data shown are representative of several independent experiments
(n ‡ 6), and the error bars represent the standard deviation (SD).
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Discussion
Hemophilia A results from varied genetic alterations of the F8
gene, including gene inversions, deletions and insertions. Intron
22 or intron 1 gene inversions account for nearly half of the
families with severe hemophilia A [23]. In mild/moderate
hemophilia A, missense mutations within the exon coding for
the three A domains or the two C domains account for most of
the mutations detected [24]. Missense mutations occur in fewer
than 20%of individuals with severe hemophilia A but nearly in
all of those with mild or moderate hemophilia [23] due to
defects in (i) protein and intracellular trafficking, (ii) VWF
interaction, (iii) thrombin activation, (iv) stability of FVIIIa, (v)
phospholipid binding, and (vi) interaction with FIXa. Point
mutations in the nucleotide sequence resulting in splicing
errors, rare small rearrangements and promoter mutations also
account for hemophilia with varying phenotypes [6].
Detection and identification of F8 gene mutations has been
demonstrated to predict disease severity, the likelihood of
inhibitor development and the success of immune tolerance
induction (ITI) therapy for FVIII inhibitor patients [6,25–27].
Since the first sequences of the human F8 gene were published,
various studies have been conducted on the mechanisms of
hemophilia A. Although investigation into the structural and
functional roles of the FVIII A and C domains has progressed
[28], there has not been extensive characterization of the FVIII
B-domain [7]. FVIII and FV comprise the same basic domain
structure and therefore share structural and functional features.
Despite these similarities, there is a marked difference in rates
of secretion between the two proteins in vitro, with FVIII being
less efficiently secreted. Removal of the B domain of FVIII
does not impair FVIII activity and results in an increased
expression of mRNA [29]. However, this does not result in
more efficient secretion due to intracellular retention of the
primary translation product. Nevertheless, the net balance is
improved expression of B-domain deleted (BDD) FVIII
compared with FVIII WT in vitro [20]. A significant portion















































Fig. 3. In vivo expression and hemostatic efficacy of factor (F) VIII B domain mutants in a hemophilia Amouse model. (A) FVIII activity in the plasma of
hemophilia Amice was measured by a COAMATIC chromogenic assay following transient expression of the indicated FVIII constructs by hydrodynamic
tail vein injection as described under Methods. Data presented (s) represent multiple independent expression studies (n ‡ 5) with the mean indicated by a
bar. No statistical difference was observed between FVIII wild type (WT) and the B domainmutants, H1047Y, D1241E, N1441K and E1579D. The FVIII
activity of the controls, A284E and R2150C, however, was significantly lower than FVIII WT (P < 0.05). (B) Hemophilia A mice were subjected to a tail
clip bleeding assay following in vivo expression of FVIIIWT and B domain mutants and blood loss over 10 min was quantified. C57BL/6J and hemophilia
A mice were included as positive and negative controls, respectively. Data presented (s) are from several independent expression studies (n ‡ 5) with the
mean indicated by a bar. No significant difference was observed between FVIII WT and the B domain mutants.
1188 K. Ogata et al
 2011 International Society on Thrombosis and Haemostasis
in its retention within the endoplasmic reticulum (ER). FVIII is
co-translationally translocated into the lumen of the ER where
it folds and assembles into its tertiary structure. Within the ER,
FVIII acquires N-linked oligosaccharide structures. Productive
secretion of FVIII requires interaction with and subsequent
release from several ER chaperones, including immunoglobulin
binding protein, calnexin (CNX) and calreticulin (CRT). CNX
and CRT both display substrate specificity for glycoproteins
containing partially glycosylated N-linked core oligosaccha-
rides. Interaction of FVIII with CNX and CRT is mediated in
part by interaction with N-linked oligosaccharides within the
B-domain. Properly folded FVIII is released from these
chaperones but requires interaction with the mannose-binding
lectin complex LMAN1/MCFD2 for efficient transport from
the ER to Golgi apparatus. Recent work has also demon-
strated that LMAN1 directly interacts with FVIII and that
high mannose-containing oligosaccharides, mostly clustered
within the B-domain, provide a significant contribution to
this interaction. Thus, the N-linked oligosaccharides within
the B-domain can participate in the folding interactions
within the ER as well as potentially facilitate ER-Golgi
transport[7]. Thus, it could be postulated that missense
mutations in the B domain, particularly those that may
disrupt post-translational modifications to FVIII, could affect
its secretion efficiency.
However, none of the B domain mutants in our study would
be predicted to interfere with N-glycosylation. Two mutations,
P1641L and S1669L, are close to the intracellular cleavage site
at residue R1648 or tyrosine-sulfation sites at residues Y1664
and Y1680, respectively. Nevertheless, we did not recognize
any effect on expression or functional activity.
D1241E was previously widely reported as a missense
mutation associated with mild or severe hemophilia but recent
observations have firmly established it as a non-synonymous
single-nucleotide substitution polymorphism [30–32]. The
expression results in our study demonstrated that both FVIII
antigen levels and activity in conditioned media from cell lines
and in plasma within the hemophilia A mouse were similar to
FVIII WT. Additionally, in a tail clip bleeding assay, D1241E
exhibited hemostatic efficacy similar to FVIII WT. Similar
observations were obtained with H1047Y, N1441K and
E1579D. Accordingly, these results suggest that none of the
FVIII B domain missense mutations we investigated would be
likely to be causative of severe hemophilia A.
There are several examples where patients have been
identified with FVIII B domain missense mutations coincident
with other FVIII gene derangements. E1038K has a reported
phenotype ranging from mild to severe [14,33,34]. However, in
one of these cases [14], E1038Kwas found to be associatedwith
the intron 22 inversion, which is a known causal mutation for
severe hemophilia A. Therefore, it is quite unlikely that the
E1038K B domain missense variant is responsible for the
hemophilia A phenotype, but rather represents a polymor-
phism. Such misattribution of causation to a missense variant
highlights the potential hazards when genotyping is adopted
broadly, particularly when such information might be used to
identify carriers or utilized in prenatal decision-making. A
recent paper by Schneppenheim et al. [35] clearly emphasizes
this point in reporting that a novel rare missense variant was
mistakenly attributed to be causative of hemophilia A leading
to prenatal diagnosis and peripartal management until the
subsequent identification of the actual causative mutation in
the familys index case.
In conclusion, most missense mutations within the FVIII B-
domain would be unlikely to lead to severe hemophilia A.
Possibly additional causative mutations in these patients are
outside the targeted sequencing regions. When sequencing
patients with hemophilia A, if a B-domainmissensemutation is
identified, another causative mutation should continue to be
sought. It is also important to perform expression studies of
these novel sequence variants to prove their causative nature. A
search for other potential pathological mutations is recom-
mended within the non-analyzed sequences, such as within
introns, in the promoter region or the 3¢-untranslated region, or
specialized studies to identify duplications.
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